| Abstrakt: |
The article discusses the use of sotatercept as a next-generation therapy for pulmonary arterial hypertension (PAH). PAH is a progressive disease characterized by the narrowing of small pulmonary arteries, leading to increased pulmonary vascular resistance and right heart failure. The current treatment strategy focuses on regulating pulmonary vascular tone, but the prognosis for PAH remains poor. The STELLAR trial, a phase 3 study, found that sotatercept improved various endpoints, including the 6-minute walk distance and pulmonary vascular resistance. The drug was generally well-tolerated, with telangiectasia, increased hemoglobin levels, bleeding events, and dizziness being the most common adverse events. Sotatercept works by restoring the balance between growth-promoting and growth-inhibiting pathways in the pulmonary artery. Further research is needed to evaluate the drug's effects on different patient populations and to explore potential combination therapies. Sotatercept has been granted breakthrough therapy designation by the US FDA and priority medicines designation by the European Medicines Agency. [Extracted from the article] |
